BR0013283A - Agente farmacêutico que compreende um derivado de benzamida como ingrediente ativo - Google Patents
Agente farmacêutico que compreende um derivado de benzamida como ingrediente ativoInfo
- Publication number
- BR0013283A BR0013283A BR0013283-7A BR0013283A BR0013283A BR 0013283 A BR0013283 A BR 0013283A BR 0013283 A BR0013283 A BR 0013283A BR 0013283 A BR0013283 A BR 0013283A
- Authority
- BR
- Brazil
- Prior art keywords
- benzamide derivative
- active ingredient
- pharmaceutical agent
- formulations
- degradation products
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Patente de Invenção: "AGENTE FARMACêUTICO QUE COMPREENDE UM DERIVADO DE BENZAMIDA COMO INGREDIENTE ATIVO". Esta invenção refere-se a formulações farmacêuticas estáveis que podem ser obtidas misturando um derivado de benzamida farmaceuticamente útil ou um sal do mesmo farmaceuticamente aceitável com aditivos que não produzem facilmente produtos de degradação, combinando um sal de ácido orgânico, um composto de amina e uma substância básica inorgânica, produzindo formulações sólidas pelo método de granulação seca e adicionalmente ajustando o pH das formulações líquidas em 4 a 12. Formulações farmacêuticas que produzem poucos produtos de degradação e que são suficientemente estáveis para ser usadas como drogas médicas podem ser obtidas
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP22955199A JP2001064177A (ja) | 1999-08-16 | 1999-08-16 | ベンズアミド誘導体を有効成分とする製剤 |
PCT/EP2000/008011 WO2001012193A1 (en) | 1999-08-16 | 2000-08-16 | Pharmaceutical agent comprising a benzamide derivative as active ingredient |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0013283A true BR0013283A (pt) | 2002-04-23 |
Family
ID=16893948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0013283-7A BR0013283A (pt) | 1999-08-16 | 2000-08-16 | Agente farmacêutico que compreende um derivado de benzamida como ingrediente ativo |
Country Status (29)
Country | Link |
---|---|
EP (1) | EP1207881B1 (pt) |
JP (2) | JP2001064177A (pt) |
KR (1) | KR100683876B1 (pt) |
CN (1) | CN1205931C (pt) |
AR (1) | AR031074A1 (pt) |
AU (1) | AU780151B2 (pt) |
BG (1) | BG65662B1 (pt) |
BR (1) | BR0013283A (pt) |
CA (1) | CA2380757C (pt) |
CY (1) | CY1116273T1 (pt) |
CZ (1) | CZ302924B6 (pt) |
DK (1) | DK1207881T3 (pt) |
EE (1) | EE05331B1 (pt) |
ES (1) | ES2536705T3 (pt) |
HK (1) | HK1046501B (pt) |
HR (1) | HRP20020181B1 (pt) |
HU (1) | HU230386B1 (pt) |
IL (1) | IL148169A0 (pt) |
MX (1) | MXPA02001575A (pt) |
NO (1) | NO328957B1 (pt) |
NZ (1) | NZ517356A (pt) |
PL (1) | PL201388B1 (pt) |
PT (1) | PT1207881E (pt) |
RU (1) | RU2257206C2 (pt) |
SK (1) | SK287547B6 (pt) |
TW (1) | TWI245630B (pt) |
UA (1) | UA73316C2 (pt) |
WO (1) | WO2001012193A1 (pt) |
ZA (1) | ZA200201466B (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001081031A (ja) * | 1999-08-30 | 2001-03-27 | Schering Ag | 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤 |
AU2001288102A1 (en) * | 2000-09-22 | 2002-04-02 | Takeda Chemical Industries Ltd. | Solid preparations |
AU2003220119A1 (en) | 2002-03-07 | 2003-09-22 | University Of Delaware | Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea |
GB0316206D0 (en) | 2003-07-10 | 2003-08-13 | Glaxo Group Ltd | Pharmaceutical formulation |
EP2135620A4 (en) | 2007-03-28 | 2010-12-29 | Santen Pharmaceutical Co Ltd | AGAINST OKULAR HYPOTONIA CONNECTED TO HISTONE DEACETYLASE INHIBITION AS AN ACTIVE SUBSTANCE |
KR101405615B1 (ko) * | 2007-08-27 | 2014-06-12 | (주)아모레퍼시픽 | 조성물 내 pH 조절을 통해 안정화된 벤즈아미드 화합물을함유하는 피부 외용제 조성물, 및 그 벤즈아미드 화합물안정화 방법 |
GB2462893B (en) * | 2008-08-29 | 2010-10-13 | Bayer Schering Pharma Ag | N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B |
NZ591387A (en) * | 2008-08-29 | 2012-03-30 | Bayer Pharma AG | N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275) polymorph b |
WO2014163132A1 (ja) * | 2013-04-04 | 2014-10-09 | 第一三共株式会社 | アミノカルボン酸の塩の固形組成物 |
EP3272345B1 (en) | 2015-03-19 | 2019-10-16 | Daiichi Sankyo Company, Limited | Solid preparation containing antioxidant agent |
EP3437639A1 (en) | 2015-03-19 | 2019-02-06 | Daiichi Sankyo Company, Limited | Solid preparation containing colorant |
WO2020153520A1 (ko) * | 2019-01-25 | 2020-07-30 | (주)아모레퍼시픽 | 벤조산아마이드 화합물 및 용해보조제를 포함하는 조성물 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3354090B2 (ja) * | 1996-09-30 | 2002-12-09 | シエーリング アクチエンゲゼルシャフト | 分化誘導剤 |
US6174905B1 (en) * | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
-
1999
- 1999-08-16 JP JP22955199A patent/JP2001064177A/ja active Pending
-
2000
- 2000-08-07 TW TW089115860A patent/TWI245630B/zh not_active IP Right Cessation
- 2000-08-15 AR ARP000104212A patent/AR031074A1/es active IP Right Grant
- 2000-08-16 EE EEP200200073A patent/EE05331B1/xx unknown
- 2000-08-16 SK SK209-2002A patent/SK287547B6/sk not_active IP Right Cessation
- 2000-08-16 RU RU2002106815/15A patent/RU2257206C2/ru active
- 2000-08-16 MX MXPA02001575A patent/MXPA02001575A/es active IP Right Grant
- 2000-08-16 EP EP00951523.0A patent/EP1207881B1/en not_active Expired - Lifetime
- 2000-08-16 CN CNB008117187A patent/CN1205931C/zh not_active Expired - Lifetime
- 2000-08-16 CA CA002380757A patent/CA2380757C/en not_active Expired - Lifetime
- 2000-08-16 CZ CZ20020540A patent/CZ302924B6/cs not_active IP Right Cessation
- 2000-08-16 IL IL14816900A patent/IL148169A0/xx active IP Right Grant
- 2000-08-16 AU AU64427/00A patent/AU780151B2/en not_active Expired
- 2000-08-16 WO PCT/EP2000/008011 patent/WO2001012193A1/en active IP Right Grant
- 2000-08-16 KR KR1020027002002A patent/KR100683876B1/ko active IP Right Grant
- 2000-08-16 DK DK00951523.0T patent/DK1207881T3/da active
- 2000-08-16 ES ES00951523.0T patent/ES2536705T3/es not_active Expired - Lifetime
- 2000-08-16 JP JP2001516539A patent/JP4854158B2/ja not_active Expired - Lifetime
- 2000-08-16 UA UA2002032040A patent/UA73316C2/uk unknown
- 2000-08-16 HU HU0203226A patent/HU230386B1/hu unknown
- 2000-08-16 PT PT951523T patent/PT1207881E/pt unknown
- 2000-08-16 BR BR0013283-7A patent/BR0013283A/pt not_active Application Discontinuation
- 2000-08-16 PL PL353449A patent/PL201388B1/pl unknown
- 2000-08-16 NZ NZ517356A patent/NZ517356A/en not_active IP Right Cessation
-
2002
- 2002-02-15 NO NO20020774A patent/NO328957B1/no not_active IP Right Cessation
- 2002-02-21 ZA ZA200201466A patent/ZA200201466B/en unknown
- 2002-02-27 HR HRP20020181AA patent/HRP20020181B1/hr not_active IP Right Cessation
- 2002-03-14 BG BG106516A patent/BG65662B1/bg unknown
- 2002-10-22 HK HK02107641.6A patent/HK1046501B/zh not_active IP Right Cessation
-
2015
- 2015-05-13 CY CY20151100423T patent/CY1116273T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
CY1116273T1 (el) | Φαρμακευτικος παραγοντας που περιλαμβανει ενα παραγωγο βενζαμιδιου ως ενεργο συστατικο | |
BR0212468A (pt) | Compoto de uréia ativos como antagonistas de receptor de vanilóides para o tratamento de dor | |
AR037490A1 (es) | Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos | |
ES2063146T3 (es) | Composiciones farmaceuticas que contienen acido n-(3,4-dimetoxicinamoil)-antranilico. | |
DK1660037T3 (da) | Aripiprazol-injektionssuspension | |
GT199700095A (es) | Derivados 6,5-heterobiciclicos sustituidos. | |
IS3156A7 (is) | Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar | |
PT97689A (pt) | Processo para a preparacao de composicoes farmaceuticas incorporando como ingrediente activo isoxazol-4-carboxilamida e hidroxialquilideno-cianoacetamida | |
ATE235895T1 (de) | Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis | |
BRPI0416752A (pt) | composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica | |
DE60134245D1 (de) | (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten | |
BR9608435A (pt) | Metodo para medicação do sistema de controle inflatório e de reações inflamatórias adversas e para produção de composto para o tratamento da patologia de reações inflamatórias adversas. | |
BR9916575A (pt) | Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa | |
ATE420638T1 (de) | Stabile feste medizinische zusammensetzung für die orale verabreichung von ramosetron | |
ATE440838T1 (de) | Pharmazeutisch aktive sulfonylaminosäurederivate | |
SE0102440D0 (sv) | New compound | |
BR0010983A (pt) | Preparações para a aplicação de agentes antiinflamatórios | |
AR016382A1 (es) | Uso de un derivado del acido bencil-indazol metoxialcanoico. | |
HUP9801712A2 (hu) | Racemizálás ellen stabilizált, cilansetrontartalmú gyógyászati készítmények, előállításuk és a stabilizáló adalékanyagok alkalmazása | |
BR0011845A (pt) | Complexo farmacêutico | |
DE60217292D1 (de) | Veterinärmedizinische dermatologische zusammensetzung | |
BRPI0407529A (pt) | uso de r-10-hidróxi-10,11-dihidro-carbamazepina em dor neuropática | |
PT97164A (pt) | Processo para a estabilizacao de uma preparacao que contenham o composto 4-etil-2-hidroxi-imino-5-nitro-3-hexenamida e de composicoes farmaceuticas que o contenham | |
GEP20053581B (en) | Pharmaceutical Composition and Method for Preparation Thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 24 E 25 DA LPI. |
|
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) Free format text: NOME ALTERADO DE: SCHERING AKTIENGESELLSCHAFT |